Replies to post #186 on Evolus (EOLS)

[DewDiligence]

Addendum—The $143-150M guidance for 2022 sales equates to $36.6M per quarter, which is only a little higher than the $34.7M logged in 4Q21. Even accounting for the fact that the fourth calendar quarter is seasonally strong, the 2022 guidance appears to be a lowball figure.

[DewDiligence]

EOLS 1Q22 product_sales=$33.2M—3/31/22_cash=$106.7M—(down from $146.3M @12/31/21):

https://investors.evolus.com/press-releases-and-news/news-details/2022/Evolus-Reports-First-Quarter-2022-Results-and-Provides-Business-Update/default.aspx

1Q22 Jeuveau sales of $33.2 (including $0.7M in Canada) were -2% QoQ, consistent with seasonal trends in the aesthetics business.

EOLS now expects 2022 Jeuveau sales to be at the high end of the prior guidance range of $143-150M, but this won’t be enough to reach breakeven operations.

EOLS continues to expect the EU launch of Jeuveau/Nuceiva in 3Q22.